Renault Tobacco petitions FDA for e-cigarette regulations

Feb.14.2023
Renault Tobacco petitions FDA for e-cigarette regulations
Reynolds Tobacco Company petitions FDA for stricter regulations on disposable e-cigarettes, citing potential health risks.

On February 6th, the parent company of Vuse, Reynolds American Inc., filed a citizen petition urging the US Food and Drug Administration (FDA) to establish mandatory regulations regarding the issue of illicit sales of disposable e-cigarette products.


On February 8th, the FDA released this information on Regulations.gov in order to solicit public comments.


Source of the image: Regulations.gov


Renova Tobacco stated in a petition, "As known by the FDA, users of electronic cigarette products in the United States have increasingly favored disposable options. A new policy specifically targeting these illegally marketed disposable electronic cigarette products is now needed to better protect public health.


Renovo Tobacco is requesting that the FDA prioritize the following areas for enforcement.


Any flavored disposable electronic cigarette (excluding tobacco or mint-flavored products); any disposable electronic cigarette containing nicotine from any source outside of tobacco that has not received pre-market authorization; any disposable electronic cigarette containing nicotine from tobacco that was not on the market as of August 8th, 2016, or for which the manufacturer did not submit a PMTA by September 9th, 2020, or did submit a PMTA but was denied and not challenged in court; any disposable electronic cigarette for which the manufacturer did not (or failed to) take adequate measures to prevent underage access; any disposable electronic cigarette marketed towards minors or that may promote use by minors.


It has been reported that RJ Reynolds Vapor Co. will no longer sell disposable e-cigarettes or other e-cigarette products with flavors other than tobacco or menthol. This decision follows the approval by the US Fifth Circuit Court of Appeals of the Food and Drug Administration's (FDA) marketing refusal order (MDO) for two RJ Reynolds Vapor Co. mint-flavored pods.


Renovo Tobacco stated in regards to its expected enforcement priorities that 'such policies will remedy existing loopholes in the FDA's current tobacco enforcement efforts, particularly concerning youth-related issues.'


Reference:


1. Citizen Petition.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

US FDA Rejects Imperial Tobacco’s blu 2.4% E-Cigarette Application, Citing Failure to Prove Health Benefits Outweigh Risks
US FDA Rejects Imperial Tobacco’s blu 2.4% E-Cigarette Application, Citing Failure to Prove Health Benefits Outweigh Risks
The US Food and Drug Administration (FDA) has issued a Marketing Denial Order (MDO) for Imperial Tobacco’s blu® Disposable Classic Tobacco 2.4% e-cigarette, prohibiting its sale and distribution in the United States. FDA’s review found that the company’s Premarket Tobacco Product Application (PMTA) did not provide sufficient evidence to demonstrate that the product could help smokers fully switch to e-cigarettes or significantly reduce cigarette consumption. Instead, existing evidence suggested
Aug.20 by 2FIRSTS.ai
Research Brief | Current Use of Cigarettes, E-Cigarettes, and Cannabis Is Significantly Associated with Xerostomia
Research Brief | Current Use of Cigarettes, E-Cigarettes, and Cannabis Is Significantly Associated with Xerostomia
About 9.7% of 29,721 U.S. adults (18+) surveyed in 2022–2023 reported their mouth felt dry “frequently” or “always.” After multivariable adjustment, past-30-day use of cigarettes (AOR ≈ 1.52), e-cigarettes (≈ 1.46), or cannabis (≈ 1.57) was each linked to higher odds of xerostomia. Daily use showed stronger associations (cigarettes ≈ 1.67; e-cigarettes ≈ 1.80; cannabis ≈ 2.15). Concurrent use of all three products had the highest odds (AOR ≈ 3.80). The authors suggest dental professionals factor
Sep.12 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Michigan recalls cannabis vape cartridges containing banned chemicals from 75 dispensaries
Michigan recalls cannabis vape cartridges containing banned chemicals from 75 dispensaries
Michigan regulators and a Warren-based company recall cannabis e-liquid sold in 75 pharmacies over chemical concerns.
Sep.03 by 2FIRSTS.ai
Company | Itsuwa Technology to Establish French Subsidiary to Boost Overseas Footprint; 2024 Net Profit Down 194.47% YoY
Company | Itsuwa Technology to Establish French Subsidiary to Boost Overseas Footprint; 2024 Net Profit Down 194.47% YoY
Itsuwa Technology announced that it plans to establish a wholly owned subsidiary in Paris, France—ITSUWA FRANCE—with a registered capital of €10,000, to engage in promotion, marketing activities, and brand management. In 2024, the company’s revenue fell 12.59% to RMB 283 million, and it recorded a net loss of RMB 19.66 million. The investment aims to strengthen overseas presence and enhance brand and market responsiveness.
Sep.12 by 2FIRSTS.ai
JUUL pays $2.5 million to the U.S. state of Minnesota, with the total settlement amount reaching $60.5 million
JUUL pays $2.5 million to the U.S. state of Minnesota, with the total settlement amount reaching $60.5 million
Minnesota receives an additional $2.5 million settlement from JUUL, totaling $60.5 million for youth smoking prevention.
Aug.20 by 2FIRSTS.ai